Ep27: Severe Asthma

Pomegranate Health

Content provided by Managing Producer, Pomegranate. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Managing Producer, Pomegranate or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

6+ y ago

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on April 14, 2021 03:08 (3y ago). Last successful fetch was on October 07, 2020 06:07 (3+ y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

In at least ten percent of asthma patients, there is an excessive symptom burden despite maximum controller therapy. A rational approach to treatment requires identifying one of three endotypes with distinct pathophysiology. Eosinophilic asthma, allergic asthma, and non-eosinophilic asthma can be differentiated by markers in blood and sputum. And targeted therapies have emerged, such as monoclonal antibodies to stages in the cytokine pathway that underlies eosinophil recruitment. It’s also important to consider the co-morbidities and risk factors that contribute to the disease, and to coordinate therapy in a multi-disciplinary way.

Guests: Professor Peter Gibson FRACP (Hunter Medical Research Institute, University of Newcastle), Professor Vanessa McDonald FRCNA (Hunter Medical Research Institute, University of Newcastle). Links to resources mentioned in the podcast are provided on the RACP website.

63 episodes

#Australia #Managing Producer, Pomegranate #Medicine #Science